RT Book, Section
A1 Roberson, Erik D.
A2 Brunton, Laurence L.
A2 Hilal-Dandan, Randa
A2 Knollmann, Björn C.
SR Print(0)
ID 1162536000
T1 Treatment of Central Nervous System Degenerative Disorders
T2 Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 13e
YR 2017
FD 2017
PB McGraw-Hill Education
PP New York, NY
SN 9781259584732
LK hemonc.mhmedical.com/content.aspx?aid=1162536000
RD 2024/04/19
AB Neurodegenerative  disorders  are  characterized  by  progressive  and  irreversible  loss  of  neurons  from  specific  regions  of  the  brain.  Prototypical  neurodegenerative  disorders  include  PD  and  HD,  where  loss  of  neurons  from  structures  of  the  basal  ganglia  results  in  abnormalities  in  the  control  of  movement;  AD,  where  the  loss  of  hippocampal  and  cortical  neurons  leads  to  impairment  of  memory  and  cognitive  ability;  and  ALS,  where  muscular  weakness  results  from  the  degeneration  of  spinal,  bulbar,  and  cortical  motor  neurons.  Currently  available  therapies  for  neurodegenerative  disorders  alleviate  the  disease  symptoms  but  do  not  alter  the  underlying  neurodegenerative  process.